Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

4Total

Not Applicable (3)

P 1 (1)

Trial Status

Completed4

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (4)

Showing 4 of 4 trials

NCT06723340Not ApplicableCompleted

Dermatological Assessment of Primary Dermal Irritability Accumulated, Sensitization, Photoallergy and Photosensitization of a Scar Gel

NCT06710600Not ApplicableCompletedPrimary

Phototoxicity of Frequently Prescribed Medicines

NCT03892564Phase 1CompletedPrimary

Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream

NCT03108209Not ApplicableCompletedPrimary

Prevention of Phototoxicities in Patients Undergoing Vemurafenib Treatment

Showing all 4 trials

Phototoxicity